The House of Representatives today voted 230-192 to approve the Lower Prescription Drug Costs Now Act (H.R. 3), legislation that would make changes to the Medicare program in an effort to lower prescription drug prices. According to a legislative summary, the bill would allow the Department of Health and Human Services to negotiate prices for up to 250 drugs without competition. It also would require drug makers to pay rebates to Medicare if their prices increase faster than inflation; cap annual out-of-pocket costs for Part D beneficiaries at $2,000; and expand access to the Part D low-income subsidy and Medicare Savings Program, among other provisions.

As amended on the floor, the bill also would create an HHS grant program to help hospitals in rural and medically underserved areas start a graduate medical education program or partner with a hospital that has an existing program. Rep. Tom O’Halleran, D-Ariz., introduced the amendment.

The Senate is not expected to vote on the legislation.

Related News Articles

Headline
The RAND Corporation May 13 released its latest hospital pricing report, which focuses on prices paid for care at the hospital and service-line level. In…
Headline
AHA submitted a statement May 8 to the House Ways and Means Committee for a markup session on proposed legislation impacting telehealth access for patients and…
Headline
The Centers for Medicare & Medicaid Services May 3 announced the opening of the comment period for the Inflation Reduction Act’s Medicare Drug Price…
Headline
The Medicare Hospital Insurance Trust Fund will have sufficient funds to pay full benefits until 2036, according to the latest annual report by the Medicare…
Headline
The departments of Health and Human Services, Labor, and the Treasury May 1 released a new process for resubmitting disputes under the No Surprises Act…
Headline
Mounting pressures on the health care workforce have created a crisis with short-term staffing shortages and a long-range picture of an unfulfilled talent…